Date: Tuesday 24 November, 7pm-8pm
Venue: Online event
Register: Here
Join Billy Boyle, CEO of Owlstone Medical to hear more about the platform and how it is being used to advance the early detection of disease. Owlstone Medical’s vision is to save 100,000 lives and $1.5 billion in healthcare costs by realizing the enormous promise of breath-based diagnostics through the development and application of Breath Biopsy. Breath Biopsy has the potential to detect volatile organic compounds produced or modified by metabolic processes within the body – changes in which can be characteristic of a specific disease. This event is part of the new series of the ‘CBC on Virtual Tour’ - the chance to learn more about the Cambridge Biomedical Campus where over 20,000 people at the forefront of the changing face of healthcare are working.
